Professor John Crown Consultant medical oncologist at St Vincent Hospital, Dublin Clinical trials of new breast cancer drug lapatinib.
Просмотров: 738 ecancer
Lapatinib (INN) or lapatinib ditosylate (USAN), also known as GW572016, is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. http://en.wikipedia.org/wiki/Lapatinib Generated using ViewMol3D: http://www.meteo.mcgill.ca/andrew/vm3
Просмотров: 7666 RedAndr
In this segment, panelists discuss the role of the TKI lapatinib in the adjuvant, neoadjuvant, and metastatic setting for patients with HER2-positive breast cancer. To view more from this discussion, visit http://www.onclive.com/peer-exchange/breast-cancer-therapies
Просмотров: 1142 OncLiveTV
Incorvati ja(1), shah s, mu y, lu j 10, breast cancer targeted therapies are used to treat patients whose cells overexpress certain characteristic proteins on their the johns hopkins center offers biologic therapy for treatment of 20, drugs or treatments that block spread and growth by targeting molecules 31, learn about types available you if have been diagnosed with her2 positive & how they work herceptin (trastuzumab), a approved people cancers, metatstatic 15, is model disease development both associated prognostic predictive biomarkers here, we review most current information regarding emerging. Androgen receptor targeted therapies in breast cancer. Months find out about the different kinds of target therapy, including most well known kind therapy currently in use, trastuzumab (herceptin) a current focus breast cancer research is to drugs that work by targeting specific molecules involved development 3, 2011 recent years description defined molecular subtypes cancer, together with identification driving genetic j hematol oncol. Lapatinib is used to treat advanced breast cancer, most often when trastuzumab no longer working. How do breast cancer targeted therapies work? Breast learn about designed to attack certain cells. It is a pill taken daily. Targeted therapies are generally less likely than chemotherapy to harm normal, healthy cells however, targeted drugs often have severe side effects standard. It uses the body's own immune system to act on cancer cells, while 21, sive review emerging targeted therapies for treating tnbcs, including neous than traditionally thought, and breast subtypes were 16, importance androgen receptor (ar) pathway is as a potential therapeutic target in. We excluded trastuzumab from this review, because targeted therapy is usually used to treat breast cancer. 14, lapatinib (tykerb) this is a type of targeted drug known as a kinase inhibitor. Beatson and colleagues published the first cases of young women in which they observed a response on surgical measures now targeted therapies are drugs used to treat certain types cancer cells. Targeted therapies trastuzumab and others targeted cancer fact sheet national institutetargeted drug therapy for breast the benefit of her2 on overall survival carememorial sloan kettering ncbi nih. Thousands of women with breast 7, webmd looks at a treatment for cancer known as targeted therapy. Targeted therapies include trastuzumab (herceptin), pertuzumab (perjeta) and several targeted are directed against her 2, including which is approved to treat certain breast stomach cancers that the drugs known as therapy help stop cancer from growing spreading. It is typically used along with certain chemo or hormone therapy drugs 26, targeted cancer therapies are treatments that target specific characteristics of cells, such as a protein allows the cells to grow in rapid abnormal way. They work by learn more about targeted therapy for breast cancer at ctca, herceptin is just one type of drug available. Targeted therapy for her2 positive breast cancer. It uses drugs to target specific molecules (such as proteins) on cancer cells or inside them 26, in 1896, g. Learn how targeted drug therapies interfere with cancer cell growth on a 17, seven rcts evaluated the os of her2 targeting in second line (breast res treat 112 533 43, 2008)) to 30. Targeted therapy of breast cancer fulltext oncology research targeted therapies expert discusses state bone in. Targeted therapy targeted for breast cancer american society treatment. Googleusercontent search. Html url? Q webcache. Targeted therapies for triple negative breast cancer cell press. Targeted (biological) therapies for breast cancer information and targeted therapy molecular mechanisms of patients could be spared debilitating side effects with treating biological webmd. Her2 targeted therapy for early stage breast cancer a emerging therapies journal of clinical canadian society. Brufsky, md, phd, discusses considerations for using denosumab and zoledronic acid in patients with breast cancer trastuzumab (herceptin) is a targeted therapy which reduces the risk of coming back women her2 positive 22, recent years, clinical trials investigating new drugs therapeutic combinations have led to promising advances 2, could be spared debilitating side effects treatment, five year study shows. Targeted therapy for her2 positive breast cancertargeted therapies in cancer new challenges to fight against biologic targeted johns hopkins what are cancer? Breast living beyond. About herceptin (trastuzumab) her2 targeted cancer therapy. Common targeted therapies available in australia target her2 positive breast cancer 27, adam m. Targeted therapy targeted for breast cancer american societytargeted national foundation. To date, ar targeted drugs.
Просмотров: 126 BEST HEALTH Answers
Scientist in Europe have found a leap forward for breast cancer. One in eight women will develop breast cancer at some point in their lives, but a recent study in Amsterdam have found a way to get rid of it once and for all. Breast Cancer Breakthrough Research presented by Professor Nigel Bundred at the European Breast Cancer Conference in Amsterdam explained that they had tested the effectiveness of a pair of drugs known as Herceptin (a.k.a trastuzumab) and Lapatinib. These drugs are already used in breast cancer treatments, but this is the first time they were combined and used before surgery and chemotherapy. They found out that if these two drugs were combined together, they were able to eliminate some types of breast cancer in just 11 days. The study, which was funded by Cancer Research UK, proposed to use these drugs to combat a protein called HER2 (human epidermal growth factor receptor 2), which affects the growth and division of cancer cells. It’s also more likely to return than other cancer types. What also makes this treatment so appealing is the fact that it eliminates the need for chemotherapy and surgery. It also has some side effects like hair loss, vomiting and fatigue, making treatment less impactful on the body. Chemo is not entirely effective, nor is it the right choice for a lot of patients, so any alternatives are welcomed. Study Results 257 women with HER2 positive breast cancer were selected for the study. Half of them were put on the drug combo while the other half were a control group. After two weeks, 11% of the participants receiving the combo had no cancer cells remaining, while another 17% saw drastically reduced tumors. The control group, which received just Herceptin, saw none of the participants cancer-free and only 3% experiencing a reduction in tumor size. Clearly, the combination of drugs was powerful. Unfortunately, Herceptin's licensing only allows it to be available in conjunction with chemotherapy. Hopefully, the results of this study can change that.
Просмотров: 10338 Direct Trend
SUBSCRIBE NOW FOR MORE CONTAGIOUSLY INSPIRING STORIES: http://bit.ly/BrightVibesSubscribe A recent trial has shown amazing potential in the fight against the most common type of cancer for women. Due to a new combination of medicines, some types of breast cancer were eliminated in just 11 days. Breast cancer is the most common cancer among women worldwide. Early detection is important. Treatments currently available include medicine, chemotherapy and surgery. The new combination of Trastuzumab and Lapatinib, however, has shown astonishing results. At the European Breast Cancer conference, Professor Nigel Bundred presented research demonstrating the effectiveness of these drugs when used together. 17 per cent of the cancers showed dramatically shrunken tumours and 11 per cent had disappeared in just two weeks. These drugs target a protein called Her2, which affects growth and division of cancer cells. Another positive aspect of this treatment is that it could make chemotherapy and surgery obsolete. The long-term effects still need to be studied, but it appears to be a major step forward. Unfortunately, due to problem’s with the drugs’ licensing, it’s often only available when combined with chemotherapy. Hopefully the new research and some media attention will change that. Share if this breakthrough makes you excited about the future for cancer sufferers. What do you think about this new research? Has it given you hope? We'd love to hear your thoughts in the comments below. And please share if you like the video. ----- Click here for the full story: http://bit.ly/FIGHTbreastCancer Check out our playlist for more inspiring BrightVibes originals http://bit.ly/BrightVibesOriginals Visit BrightVibes.com for more contagiously inspiring stories http://brightvibes.com Other ways to connect with us… FACEBOOK: http://facebook.com/brightvibes TWITTER: https://twitter.com/brightvibes_com INSTAGRAM: http://instagram.com/brightvibesmedia
Просмотров: 53 BrightVibes
► New lab study reveals how breast cancer drug can accelerate cancer cell growth ► The breast cancer drug lapatinib which is designed to shrink tumours can sometimes cause them to gro... ► Subscribe: ► Photo & Content Source : ========================================= ► NBA Topic Channel dedicated to sharing the latest news around the world. ► Videos can use content-based copyright law contains reasonable use Fair Use (https://www..com/yt/copyright/). ► With the above criteria, if there is any breach of the principles of Community, law on copyright then please comment on the video
Просмотров: 1 Health and Life
Patients whose disease progresses or relapses on trastuzumab now have 3 new therapeutic options: lapatinib, pertuzumab, and T-DM1. Each of these agents has a unique mechanism of targeting HER-2 signaling and cross-talk among HER family members. When considering treatment for patients past the first-line setting, the goals of therapy should be to improve survival and minimize treatment-related toxicity. Only T-DM1 has demonstrated survival benefits over other traditional choices, such as lapatinib and capecitabine, and should therefore represent a standard of care for second-line patients. Dual HER2 blockade with lapatinib and trastuzumab also led to a survival advantage over lapatinib alone in more heavily pretreated patients than those enrolled in EMILIA. This combination of HER2- targeting agents also offers a low toxicity profile. Finally, once T-DM1 and lapatinib strategies have been exhausted, continuation of trastuzumab in combination with chemotherapy has proven activity. The increasing number of options in the second-line setting and beyond is good news for patients faced with trastuzumab-refractory metastatic breast cancer
Просмотров: 56967 ImedexCME
Breast cancer is the most common type of cancer worldwide, affecting nearly 1.7 million women each year. Research by Professor Nigel Bundred has developed a pair of drugs known as Herceptin and Lapatinib. When combined these two drugs are capable of eliminating most types of breast cancer within 11 days WITHOUT the use of surgery or chemotherapy. After successful trials and overwhelming positive results the drug is not licensed to be used unless paired with invasive chemotherapy. But many are trying to change that! Comment below if you know someone that has been affected by breast cancer! Like our Facebook page at https://www.facebook.com/ShareableWorld/
Просмотров: 468 Shareable World
Dr. Edith Perez, Mayo Clinic Oncologist, talks about how adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a majority of women with early stage HER2-positive breast cancer. Read the blog post on this at: http://mayocl.in/RntMhj
Просмотров: 329 Mayo Clinic
Mechanism of action of a very recent and promising new therapy in cancer: Pertuzumab which is a monoclonal antibody that inhibits HER2 dimerization and thus cancer progression in association with Trastuzumab (Herceptin). Association website: http://www.efp-online.fr Online education: http://www.invivoveritas.fr
Просмотров: 34162 AssoEFP
THE breast cancer treatment, Tykerb, has been placed on the the Pharmaceutical Benefits Scheme (PBS), making it cheaper for women affected by an aggressive form of the disease. Federal Health Minister Nicola Roxon announced today that from May 1, Lapatinib, known commercially as Tykerb, would be subsidised under the scheme's arrangements. Tykerb had been found to slow the progress of and improve symptoms associated with advanced HER-2 positive breast cancer, Ms Roxon said. "Without any subsidy, the medicine would cost women between $3500 and $4000 each month," she said. "Lapatinib will be available to people with HER-2 positive metastatic or advanced breast cancer for whom other treatments have proved ineffective." The drug is used in treating a particularly aggressive form of disease known as advanced HER-2 positive breast cancer. "HER-2 positive breast cancer is an aggressive form of cancer that particularly impacts upon younger women," Ms Roxon said. "Around 87 per cent of patients diagnosed with advanced breast cancer will die from the disease within five years.
Просмотров: 1032 jupjupz
Presented At: Cancer Research & Oncology 2018 Presented By: Kevin Williams, PhD - Associate Professor, Biomanufacturing Research Institute and Technology Enterprise, NC Central University Speaker Biography: Dr. Kevin P. Williams, Ph.D. is an Associate Professor in the Department of Pharmaceutical Sciences and a faculty member of BRITE at North Carolina Central University. Dr. Williams has over 25 years combined experience in both academic and biopharmaceutical-based research with a focus on cancer and drug discovery. Dr. Williams received his B.Sc. in Biochemistry from the University of Bath in the UK and received his Ph.D. in Biochemistry from the University of Cambridge (UK). He completed his postdoctoral work at Massachusetts General Hospital and the Joslin Diabetes Center in Boston. Prior to joining NCCU in 2007, he spent six years as a Senior Scientist at Biogen in the Department of Protein Engineering and four years at Amphora Corp as Director of Enzyme Drug Discovery. At NCCU he has obtained NIH and DOD research support and mentored 12 Masters level graduate students. His lab currently focuses on identifying novel modulators of the hedgehog pathway. Dr. Williams serves as course director and main instructor for the undergraduate bioprocessing and graduate-level biomanufacturing classes. He is co-author of over 45 publications and co-inventor on 9 patents. Webinar: Drug Targeting for Inflammatory Breast Cancer Webinar Abstract: Two projects looking at novel approaches to targeting inflammatory breast cancer will be presented. Inflammatory breast cancer (IBC) is a unique, understudied, and most lethal subtype accounting for ~15% of all breast cancer deaths. IBC is characterized by Stage III or IV at diagnosis, no solid tumor, typically not detected by mammogram and rapid progression from onset of disease. The incidence of IBC is higher in younger patients and in women of African descent. There are limited treatment options for IBC. Targeted therapy with drugs that target HER1/2 (if the cancer is HER2-positive) e.g. the HER1/2 tyrosine kinase inhibitor lapatinib are one of the few treatment options but drug resistance is observed in the clinic. In the first project, we characterized a novel isogenic-derived progression model of lapatinib drug resistance and re-sensitization using the IBC cell line SUM149. In this study, lapatinib-resistant rSUM149 cells showed cross-resistance to a number of the drugs previously shown to act on the parental cells. The rSUM149 cells had increased levels of anti-apoptotic proteins, increased antioxidant expression, and decreased ability to accumulate reactive oxygen species (ROS), all of which lead to inhibition of drug-induced apoptosis. These results strengthen the need for novel strategies to modulate cellular redox to overcome drug resistance in IBC. In the second project, a major effort of our lab is to identify novel modulators of the hedgehog pathway in breast cancer. Dysregulation of the developmental Hedgehog (Hh) pathway is observed in many cancers with activation of the downstream Hh pathway effector GLI1 being linked to tumorigenesis and invasiveness in breast cancer including IBC. We have profiled a collection of GLI-directed small molecule antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of IBC, with a subset including the direct GLI1 binder GANT61 demonstrating activity in vivo. Further, we have also shown that GLI1 is directly phosphorylated by the kinase DYRK1A at a site within its putative nuclear localization sequence suggesting a possible mechanistic role in modulating its function. Utilizing the BRITE Institute’s capabilities in high-throughput screening we have identified novel and potent DYRK1A inhibitors that are being assessed for cellular and in vivo efficacy. Learning Objectives: 1. Understand some of the new and novel approaches to targeting inflammatory breast cancer 2. Understand why there are limited treatment options for IBC Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/cancer-research-oncology-2018) 2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/cancer-research-oncology-2018) 3. Click Here to get your PACE (Expiration date – October 11, 2020 10:30 AM)– https://www.labroots.com/credit/pace-credits/3117/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 6 LabRoots
Kadcyla (T-DM1) is a FDA approved breast cancer drug that targets cancer cells while leaving healthy cells alone. Visit http://oacancer.com/kadcyla_t-dm1/ for more information on this promising new drug. These videos are produced by Dr. Stephen J. Lemon, who now practices with the Overlake Cancer Center in the Seattle area. These videos are intended to help provide useful cancer information to cancer patients and survivors. Oncology Associates provides a full-range of personalized cancer treatment at two Omaha clinics, as well as at cancer treatment clinics throughout Nebraska, which include Blair and Norfolk. The cancer physicians of Oncology Associates include: * Irina E. Popa, MD To learn more about OA's approach to personalized cancer treatment as well as about the oncologists and staff, please visit http://www.oacancer.com
Просмотров: 7659 Oncology Associates
Researchers in England report a two-drug combination given to patients ahead of shrank breast cancer tumors significantly in only 11 days. After being given lapatinib and trastuzumab after diagnosis and before other treatmentsPatients diagosed with a specific form of breast cancer, human epidermal growth factor receptor 2, said their tumors shrinked in size or even dissapeared. More Trials are needed to confirm what Scientists are calling "mind-blowing" results. Data on 130 women included in part one showed the combination of drugs was so effective against cancer http://www.upi.com/Health_News/2016/03/10/Drug-combination-shrank-breast-tumors-in-11-days/6171457634437/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Просмотров: 530 Wochit News
Prof Bundred talks to ecancertv at SABCS 2015 about early results from the UK EPHOS-B trial on the effect of peri-operative anti-HER2 therapy on cancer cell proliferation and cell survival. The UK EPHOS-B trial is an ongoing, multicentre, two-part randomised trial in patients with operable newly diagnosed HER2 primary breast cancer. The Independent Data Monitoring Committee for the trial has agreed partial release of the data from the first part of the study only in which women about to undergo surgery were randomised to receive peri-operative treatment with lapatinib or trastuzumab alone, or to no treatment. With approximately 11 days’ lapatinib treatment, decreased cell proliferation (defined as a ≥30% fall in Ki67, a marker of cell proliferation) was measured in 67% of women. An increase in cell death was measured in 30% of women. The key point is that you need to know the HER2 status of women before undergoing surgery, Dr Bunsen suggests. This is not always done but if it is and women are positive it shows that giving them lapatinib as early as possible could significantly improve their outcome.
Просмотров: 79 ecancer
Dr Hecht talks to ecancer at ASCO 2013 about the Translational Research in Oncology (TRO) collaboration using lapatinib in combination with chemotherapy.
Просмотров: 234 ecancer
"A phase III randomized study of the investigational agent trastuzumab emtansine (T-DM1) versus standard therapy using capecitabine (Xeloda) and lapatinib (Tykerb) found significant and clinically meaningful improvement in progression-free survival (PFS) for T-DM1 in women with HER2-positive locally advanced or metastatic breast cancer previously treated with a taxane and trastuzumab," according to a news release. Lead author, Dr. Kimberly Blackwell, discusses the findings. For more, visit http://www.oncologypractice.com.
Просмотров: 3569 MDedge: news and insights for busy physicians
Sofia Braga discusses the results from 3 trials presented at ASCO 2017 that evaluated the role, duration and a combination of adjuvant therapy drugs (dual inhibition) in patients with HER2-positive early breast cancer. Abstracts as referenced in the ASCO 2017 programme: LBA500: APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC). 501: 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER. 502: Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer. Produced by the European Society for Medical Oncology http://www.esmo.oncologypro.org
Просмотров: 1470 European Society for Medical Oncology
Visit http://ecancer.org/ for more. At a press conference at ASCO 2014, Dr Perez (Mayo Clinic, Rochester, USA) presents the findings from a large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation), which suggest that post-surgery (adjuvant) treatment using a combination of two HER2-targeted drugs -- trastuzumab and lapatinib -- is no more effective than standard treatment with trastuzumab alone for women with early HER2-positive breast cancer.
Просмотров: 151 ecancer
Which First-Line Breast Cancer Therapy Is Right for Me. Knowing where to turn next with your breast cancer treatment can be a tough decision. But understanding the different types of therapies can help ensure you know what’s best for you. Hormone and targeted therapies. The first-line treatment for advanced hormone receptor-positive (estrogen receptor-positive or progesterone receptor-positive) breast cancer is usually hormone therapy. Tamoxifen is generally the first option for premenopausal women. If you’re post-menopausal, you’ll likely try letrozole (Femara) or fulvestrant (Faslodex) first. Side effects of hormone therapy vary with each drug, but can include: *hot flashes and night sweats. *vaginal dryness. *loss of sex drive. *mood swings. Hormone therapies can also increase your risk of blood clots, stroke, and bone loss. Two targeted therapies for postmenopausal women with advanced hormone receptor-positive/HER2-negative breast cancer are: *Palbociclib (Ibrance), which is used in combination with an aromatase inhibitor. Side effects may include nausea, mouth sores, hair loss, fatigue, and diarrhea. This medication may raise your risk for infection. *Everolimus (Afinitor), which is used in combination with exemestane (Aromasin). It’s generally reserved for use after letrozole or anastrozole (Arimidex) have failed to control the cancer. Side effects can include shortness of breath, cough, and weakness. This medication can increase the risks of infection, high blood lipids, and high blood sugar. Careful monitoring of the blood is necessary. Targeted therapies for HER2-positive breast cancer include: *trastuzumab (Herceptin). *pertuzumab (Perjeta). *ado-trastuzumab emtansine (Kadcyla). *lapatinib (Tykerb). Some of these may be more effective when used in combination with chemotherapy. Most hormonal and targeted therapies are available in pill form. If side effects get overwhelming, or your cancer continues to progress while taking hormonal or targeted therapy, changing drugs is a good strategy. If you’ve already done that and cancer is still progressing, you may have to switch to chemotherapy alone. Chemotherapy. Chemotherapy drugs are designed to kill fast-growing cells, which is why they’re so effective in destroying cancer. But there are other fast-growing cells in your body that can be damaged in the process, including: *hair follicles. *cells in your bone marrow that help form blood. *cells in your mouth, digestive tract, and reproductive system. All Photos Licensed Under CC Source : www.pexels.com www.pixabay.com www.commons.wikimedia.org
Просмотров: 5870 Best Natural Cures
Panelists discuss the combination of trastuzumab, pertuzumab, and docetaxel as frontline treatment for patients with HER2-positive metastatic breast cancer. To view more from this discussion, visit http://www.onclive.com/peer-exchange/mbc-community
Просмотров: 938 OncLiveTV
Moderator: Jens Eckstein, PhD, President, SR One Kenneth Anderson, MD, Director, Jerome Lipper Multiple Myeloma Center, Kraft Family Professor of Medicine, Harvard Medical School Jeffrey Engelman, MD, PhD, Director, Thoracic Oncology and Director, Molecular Therapeutics, Medical Oncology, MGH, Laurel Schwartz Associate Professor of Medicine, Harvard Medical School Jamie Freedman, MD, PhD, Senior Vice President, Global Clinical Development, Medimmune David Schenkein, MD, CEO, Agios Pharmaceuticals William Sellers, MD, Vice President and Global Head of Oncology, Novartis Institutes for BioMedical Research Study Designs to Meet the Challenges of Personalized Cancer Medicine Game changing modern cancer therapies—immunotherapies and targeted therapies, among others—do not by themselves meet the needs of many patients who require alternative strategies to achieve optimal therapeutic benefit. Panel experts will describe combining these therapies with other drugs, challenges and the path forward.
Просмотров: 938 World Medical Innovation Forum
Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, discusses the order that various HER2 targeted therapies should given to breast cancer patients. Tripathy explains that a hard-set guideline has not been established. He describes that it has become increasingly more likely that a patient will receive trastuzumab (Herceptin) in the adjuvant setting and that because of this HER2/neu positive recurrences usually have already received the drug, warranting a new approach. The two main choices for patients with HER2 overexpression is trastuzumab with a different chemotherapy or lapatinib (Tykerb) with capecitabine (Xeloda). It has not been established which treatment should be used first. There is evidence to support using either drug. In many cases it is acceptable to use one drug first or to interchange treatments.
Просмотров: 413 OncLiveTV
Dr Jones discusses the use of Trastuzumab (Herceptin) and Lapatinib as drugs to target the HER2 receptor and the possibility of combining these as part of a dual targeting approach, the drawbacks including side effects or resistance among patients and the services offered by HCA. Dr Alison Jones; Dept of Medical Oncology, Royal Free Hospital, London, speaking at the 7th European Breast Cancer Conference in Barcelona
Просмотров: 711 ecancer
Dr Carmen Criscitiello talks to ecancer at ESMO 2012 in Vienna about a clinical study that showed the effects of lapatinib and trastuzumab combination therapy in breast cancer patients. Results from the study showed an increase in improved pathological complete response; however, this did not translate into a higher rate of breast conservation surgery. The study looked into what factors effect the decision for surgery and early results show that the largest factor for patients wanting to receive surgery is the preplanning of the procedure. Patients feel that this is the best treatment for them because it has already been decided, despite the effects of non-surgical treatment.
Просмотров: 518 ecancer
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,firstname.lastname@example.org, https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn , ,https://plus.google.com/u/0/+AlexandrosGSfakianakis , https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ , https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA , https://twitter.com/g_orl?lang=el, https://www.instagram.com/alexandrossfakianakis/, Treatment of Metastatic HER2-Positive Breast Cancer https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/treatment-metastatic-her2-positive-breast-cancer To help doctors give their patients the best possible care, the American Society of Clinical Oncology (ASCO) asks its medical experts to develop evidence-based recommendations about specific topics in cancer care. These recommendations are for the treatment of human epidermal receptor 2 (HER2)-positive breast cancer that has spread beyond the breast. This guide for patients and caregivers is based on ASCO's recommendations. Key Messages: Several treatments are currently available that can help women with HER2-positive breast cancer continue to live and function well after diagnosis, even if it has spread. Treatment of HER2-positive breast cancer that has spread to organs other than the brain usually includes drugs called HER2-targeted therapies, which are intended to slow or stop cancer growth by blocking HER2. Surgery and radiation therapy are usually used alone or in combination for HER2-positive breast cancer that has spread to the brain to shrink or temporarily eliminate cancer from the brain. Treatments to manage the symptoms of metastatic breast cancer and the side effects of treatment are also an important part of each patient’s treatment plan. Clinical trials are also a treatment option to consider at any time during cancer care. Background Metastatic breast cancer is cancer that has spread from the breast to another part of the body or has come back in another distant location. This area of spread is called a metastasis, or metastases if there are multiple areas of spread. Breast cancer most commonly spreads to the bone, lungs, liver, and brain. It is important to remember that breast cancer that spreads to these other organs is still considered breast cancer and treated similarly. Some women are diagnosed with metastatic breast cancer after having received treatment for early-stage breast cancer. For others, the first diagnosis of breast cancer is when it has already spread. Treatment options for metastatic breast cancer depend on several factors, including where the cancer has spread, the patient’s overall health, and the levels of hormone receptors and HER2 in the tumor. Both hormone receptors and HER2 are specialized proteins. Hormone receptors are found inside breast cells and HER2 is found on the surface of breast cells. Cancers with high levels of hormone receptors, called hormone receptor-positive, use the hormones estrogen and progesterone to grow and spread. When a breast cell has abnormally high levels of the HER2 gene or the HER2 protein, it is called HER2- positive. About 15% to 20% of patients with invasive breast cancer have abnormally high levels of HER2. These cancers tend to be more likely to spread than other types of breast cancer, particularly to the brain. HER2-positive metastatic breast cancer will spread to the brain in up to half of patients. Drugs that specifically block HER2 to stop the growth of cancer cells are called HER2-targeted therapies. Examples of these drugs include trastuzumab (Herceptin), lapatinib (Tykerb), pertuzumab (Perjeta), and ado-trastuzumab emtansine (Kadcyla), commonly referred to as T-DM1. Some of these drugs may be used together with chemotherapy. Unfortunately, these drugs are not usually able to reach the brain as easily as they can reach the rest of the body, with lapatinib being a possible exception. Therefore, when cancer spreads to the brain it is usually treated with surgery and/or radiation therapy. In addition to treatment to slow, stop, or eliminate the cancer, an important part of cancer care, particularly for those with metastatic cancer, is relieving the symptoms and side effects. This is called supportive or palliative care, and it includes supporting the patient with his or her physical, emotional, and social needs. Recommendations for cancer that has spread to parts of the body other than the brain In general, HER2-targeted therapy should be added to treatment for HER2-positive breast cancer that has spread. The drugs used depend on the treatments already given and whether the cancer is hormone receptor-positive. The first set of drugs used for metastatic disease is called first-line treatment. If the cancer worsens or comes back, another reg
Просмотров: 135 Alexandros G. Sfakianakis
HER2-positive breast cancer represents 15-20 percent of all new cases of breast cancer. Eric P. Winer, MD, director of Breast Oncology at the Susan F. Smith Center for Women's Cancers, describes HER2-positive breast cancer symptoms and treatment options. To find out more visit http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Breast-Cancer-Treatment-Center.aspx Transcription: HER2-positive breast cancer represents about 15% to 20% of all new cases of breast cancer. In women who have HER2-positive breast cancer—and the occasional man, of course, who may have this—there are too many copies of the HER2 gene in the nucleus of the cancer cell, and that gives rise to too much HER2 protein on the surface of the cancer cell. As a result of HER2, the cancer cell is able to grow and spread and invade more readily. HER2 is something that is very important for the cancer, because it helps it survive and flourish, which is of course good for the cancer and bad for the patient. This used to be one of the worst subtypes of breast cancer—and it probably does tend to affect younger women a little bit more than older women, although we see it for across all ages—but what has changed is that over the past 15 years, we have developed so-called ‘targeted treatments’ for HER2-positive breast cancer. The first of those treatments is the drug Trastuzumab, which a lot of people call ‘Herceptin,’ but there are three additional targeted treatments that are now approved for HER2-positive breast cancer, which include the drug called Pertuzumab and a drug called T-DM1 and a drug called Lapatinib—all of these are very drugs for HER2-positive breast cancer. Sometimes they’re used alone. Most of the time they’re used in combination with other treatments—specifically chemotherapy or other forms of anti-HER2 treatment—and they can be very, very effective. What has changed is that as a result of these treatments, there are more women with early-stage HER2-positive breast cancer who are cured of their cancer, and even in women who have more advanced forms of cancer, who have stage 4 or metastatic HER2-positive breast cancer. These drugs have prolonged life and as importantly have dramatically affected quality of life.
Просмотров: 8752 Dana-Farber Cancer Institute
Visit http://ecancer.org/ for more. Dr Perez talks to ecancertv at ASCO 2014 about the findings from a large phase III study, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) which suggest that post-surgery (adjuvant) treatment using a combination of two HER2-targeted drugs -- trastuzumab and lapatinib -- is no more effective than standard treatment with trastuzumab alone for women with early HER2-positive breast cancer.
Просмотров: 72 ecancer
Women suffering from terminal breast cancer may be denied access to life-extending treatment. Kadcyla, a cancer drug currently available on the NHS, may be removed from the Cancer Drugs Fund if a compromise cannot be made between pharmaceutical company Roche and NICE. Reporters: Katie Thompson and Vicky Double
Просмотров: 126 eastlondonlines
Debu Tripathy, MD, professor of medicine and co-leader of the Women's Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, talks about deciding the best HER2 treatment to give a patients, he mentions that in the first-line setting the FDA indication is to receive trastuzumab. If there is a recurrence there are more choices, such as deciding between trastuzumab and lapatinib. Tripathy uses the side effect profile and consultations with patients to decide which drug to use. Each drug has different implications. Despite its larger side effect profile lapatinib has the benefit of being administered orally, which may be important to the patient. These are all items that need to be considered when choosing the best treatment.
Просмотров: 130 OncLiveTV
Dr. Angel Rodriguez - Lester and Sue Smith Breast Centre, Baylor College of Medicine, Houston - Speaking at the 6th European Breast Cancer Conference - Findings on Lapatinib's role in tackling cancer stem cells.
Просмотров: 878 ecancer
In this segment, panelists discuss the phase III MA.31 trial that examined lapatinib or trastuzumab with a taxane-based chemotherapy to treat patients with HER2-positive metastatic breast cancer. To view more from this discussion, visit http://www.onclive.com/peer-exchange/MBC-challenges
Просмотров: 298 OncLiveTV
San Antonio Breast Cancer Symposium 2010 - A discussion with Dr. Sara Hurvitz, Director of Breast Cancer, UCLA Jonsson Comprehensive Cancer Center on the Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2+ Breast Cancer.
Просмотров: 1629 Oncology.TV
Jun 23, 2010 -- Health care shares are up before the bell, while GlaxoSmithKline (GSK) won approval from the European Union for a wider use of its breast cancer drug Tyverb. The drug can now be used in combination with an aromatase inhibitor in breat cancer patients for whom chemotherapy is not used. Cytori Therapeutics (CYTX) may need to spend $10 million more and take five years longer to gain FDA approval for its body tissue repair device, according to Bloomberg.
Просмотров: 120 TradeTheTrend
The Biomarkers Consortium, a public-private alliance that includes the U.S. Food and Drug Administration, the National Institutes of Health and major pharmaceutical companies, announced the start of the I-SPY 2 trial at a news conference this morning at NIH headquarters in Bethesda, Md. The project is led by the Foundation for the National Institutes of Health. M. D. Anderson will be one of the first of 20 national clinical trial sites to open. The trial combines personalized medicine with an innovative adaptive randomization approach designed to match each womans tumor with the drug most likely to control her disease.
Просмотров: 1126 MD Anderson Cancer Center
AMSTERDAM, Netherlands—Some patients with breast cancer could soon be treated with surgery and targeted drugs without the need for chemotherapy—according to findings reported at the 2016 European Breast Cancer Conference by Judith Bliss, Professor of Clinical Trials at the Institute of Cancer Research, in Sutton, near London UK. Patients whose cancers tested positive for the HER2 molecule responded in matter of days to a combination of the two drugs lapatinib plus trastuzumab used in the brief window between diagnosis and surgery in the UK EPHOS B study—indicating that such anti-HER2 drug combinations could be effective in the months following surgery—avoiding cytotoxic side effects such as hair loss and increased risk of heart disease. SOURCE: http://www.ecco-org.eu/Events/EBCC10/Abstract-search?abstractid=25368 Abstract 6LB: “Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer - the UK EPHOS-B trial (CRUK/08/002)” AJO Cancer Spotlight: Posted April 5th, 2016 By the Audio Journal of Oncology
Просмотров: 82 Peter Goodwin
More research and advancements are happening at community hospitals in the fight against cancer. As News 13's Jay Siltzer shows us, one local women's participation through Pardee Hospital could one day impact her own community. North Henderson High School math teacher Rachel Willingham is back at work after a second bout with breast cancer. She continues fighting for her life while participating in a clinical trial that combines conventional treatment herceptin with a new drug, Tykerb. What if this is the breakthrough that's needed? If my ability and desire to help others can help someone else, then why not, said Willingham. Longterm, they are going to decide whether these two drugs together will help for progression-free survival, said Leann Noakes, RN. No matter her outcome, the 41-year-old Willingham walks tall with a smile. Cancer doesn't define who I am. That's just a small part of my life. That's a bump in the road, said Willingham. That bump in the road started as a lump in the breast four years ago that led to a cancer diagnosis and a resolve to fight like a knight. One day after her first chemo treatment in 2009, Rachel, somehow, had the energy to come here to the Knights' football game. What she discovered was immeasurable support. When they got ready to start the game, all the football players took off their helmets and they had all shaved their heads, said Willingham. Now, she returns that love by taking part in a trial that may one day set the standard of care for those players' mothers, sisters, wives and daughters affected by breast cancer. Patients at Pardee Hospital are involved in more than 50 different national and international clinical trials and studies.
Просмотров: 103 WLOS News 13